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BACKGROUND: Circulating pepsinogens can indicate atrophic gastritis, a precursor of gastric cancer. We tested the association between
gastric cancer and plasma pepsinogens and antibodies against Helicobacter pylori in a case–control study nested in a prospective cohort.
METHODS: We selected 141 gastric cancer cases and 282 incidence-density sampled controls. Plasma concentrations of pepsinogens 1 and 2
were measured using ELISA kits, and anti-H. pylori antibodies were measured using a kit specific to Chinese strains. Associations were
estimated using conditional logistic regression models adjusted for potential confounders.
RESULTS: Gastric cancer subjects were more likely to be anti-H. pylori positive than controls, 97 vs 92%. A plasma pepsinogen 1 (PG1)
concentration o50ngml
–1(15% of cases) was associated with a significantly increased risk of gastric cancer (OR 4.23; (95% CI: 1.86–9.63),
whereas a plasma pepsinogen 2 (PG2) concentration 46.6ngml
–1(75% of cases) was also associated with a significantly increased risk of
gastric cancer (OR 3.62; (95% CI: 1.85–7.09). We also found that the PG1:2 ratio had a nearly linear association with gastric cancer risk.
CONCLUSION: Lower plasma PG1:2 ratios are associated with a higher risk of gastric cancer. Furthermore, it appears that circulating
pepsinogens 1 and 2 may be independently associated with the risk of gastric cancer.
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Atrophic gastritis, a condition characterised by loss of glands and
specialised cells in the stomach, is a precursor lesion of gastric
cancer (Correa, 1992; Sipponen and Graham, 2007), the second
most common cause of cancer death worldwide (Kamangar et al,
2006b). Atrophic gastritis may be diagnosed by histological
examination of gastric biopsies, measuring gastric maximum acid
output, or measuring serum or plasma concentration of proteins
released from the gastric cells, such as pepsinogens (Samloff et al,
1982; Ley et al, 2001). Pepsinogens are proteinases that are mainly
secreted by gastric cells and are classified into two major types:
pepsinogen 1 (PG1) and pepsinogen 2 (PG2) (Samloff and Taggart,
1987). PG1 is secreted from the gastric fundic mucosa and PG2 is
secreted from the cardiac, fundic, and antral mucosa of the
stomach, and also from the duodenal mucosa (Samloff and
Taggart, 1987). Helicobacter pylori infection is a strong risk factor
for the development of both atrophic gastritis and gastric cancer
(Forman et al, 1991; Parsonnet et al, 1991; Nomura et al, 2005;
Kamangar et al, 2006a).
Few studies have examined the association between PG2
alone and gastric cancer risk, but a low concentration of PG1 or
a low PG1 to PG2 ratio (PG1:2 ratio) in the serum or plasma is
an indicator of atrophic gastritis and is associated with an
elevated gastric cancer risk (Stemmermann et al, 1987; Fukuda
et al, 1995; Ren et al, 2009). Most previous studies have
used specific cut points to determine low levels of PG1 or PG1:2
ratio, but these cut points have varied across studies (Weck and
Brenner, 2006; Brenner et al, 2007). Some of these cut points
were initially determined by comparing the circulating PG1:2 ratio
to a presumed reference standard, histological examination of
gastric biopsies. However, histological examination of gastric
biopsies cannot definitively diagnose atrophic gastritis because
only a very small proportion of the stomach mucosa is examined,
which may lead to sampling error (Satoh et al, 1998), and
because of considerable interobserver variability in histological
readings (Andrew et al, 1994). An alternative approach may
be to examine PG concentrations as continuous or ordinal
variables. Two recent studies have shown that using serum
PG1:2 ratio as quartiles or as a continuous variable was
more informative in predicting the risk of gastric cancer (Ren
et al, 2009) or oesophageal squamous dysplasia (Kamangar et al,
2008).
We conducted this prospective nested case–control study to
examine different methods of using PG1, PG2, or the PG1:2 ratio
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cohort of women in Shanghai, China.
MATERIALS AND METHODS
Study participants
The case and control subjects were selected from women who
participated in the Shanghai Women’s Health Study (SWHS) and
provided a blood sample. Details of the study design have been
previously published (Zheng et al, 2005). In brief, a total of 81170
women aged 40–70 years and residing in seven urban commu-
nities of Shanghai were invited to participate in the study. Of these,
75221 (93%) women completed the baseline survey between 1996
and 2000. After exclusion of study subjects o40 or 470 years of
age and those who had malignancies at baseline, 73222 women
remained in the analytic cohort. A total of 154 incident gastric
cancer cases were diagnosed through December 2005, of whom 141
had plasma available for H. pylori and pepsinogen assays and were
included as cases in this study. Two controls were matched to each
case for menopausal status at sample collection, age (±2 years),
date of sample collection (1 month), time of sample collection
(morning or afternoon), and time interval since last meal (2h).
Controls were also free of any cancer at the time of cancer
diagnosis for their corresponding case. No subjects were allowed to
be sampled multiple times.
Collection of data and biological samples
At study baseline, after obtaining informed consent, information
on demographic characteristics, education and income, lifestyle and
habits, diet, and several other factors were obtained via a
combination of self-administered questionnaires and in-person
interviews. Among cohort members, 56831 (76%) women provided
a 10ml blood sample drawn into an ethylene diamine tetraacetic
acid Vacutainer tube (Becton, Dickinson and Company, Franklin
Lakes, NJ, USA). Samples were kept in a portable insulated bag with
ice packs (0–41C) and processed within 6h for long-term storage at
 701C. Each woman also filled out a biospecimen collection form at
the time they provided the sample.
Outcome assessment
Outcome ascertainment was conducted by in-person interviews, and
by annual record linkage to the population-based Shanghai Cancer
Registry and the Shanghai Vital Statistics Unit. Participants were
followed up by an in-home visit every 2 years to record details of
their interim health history, including any cancer diagnosis and by
record linkage with Shanghai Tumor Registry database. In the
follow-up surveys, interviewers were able to interview and follow-up
with 99.8% (2000–2002), 98.7% (2002–2004), and 96.7% (2004–
2007) of cohort members or their next of kin. For cancer patients,
information on date of diagnosis was collected and medical charts
and diagnostic slides were reviewed to verify diagnosis.
Pepsinogen assays
Plasma PG1 and PG2 were measured using an enzyme-linked
immunosorbent assay (Biohit ELISA kit, Biohit, Helsinki, Finland) at
the Karolinska Institutet, Sweden, by trained personnel unaware of
subjects’ case status according to the manufacturer’s instructions.
The quality control samples provided with the kits were
included on each assay plate with additional quality control
samples using pooled plasma from cohort members. The kit
quality control samples showed CVs of 3.1 and 3.7% for PG1
and PG2, respectively. The cohort plasma quality control samples
(two per plate and 14 in total) showed CVs of 5 and 17%,
respectively.
H. pylori assays
Plasma was evaluated for IgG antibodies to whole-cell and CagA
H. pylori antigens using the China-specific ELISA (Biohit ELISA
kit) and immunoblot (Helicoblot 2.0; Genelabs Diagnostics,
Singapore) assays, respectively. All assays were done in Karolinska
Institutet, Sweden. The kit quality control samples showed a CV of
6.4%. For the pooled plasma sample the CV was 4.5%. For
immunoblot analysis, we used the criteria recommended by the
manufacturer to interpret the CagA bands.
Similar to previous studies, H. pylori seropositivity cut point was
defined as optical density ratios X1.0 for the whole-cell antibodies
(Kamangar et al, 2006a, 2007). H. pylori positivity was analysed as
a dichotomous variable. Positive subjects were defined as those
positive for whole-cell antibodies or CagA immunoblot, and
negative subjects were those negative for both markers.
Statistical analysis
Statistical analyses were done using SAS version 9.1 (SAS Institute
Inc., Cary, NC, USA). We used two-sided P-values throughout the
paper and considered those o0.05 to be statistically significant.
We calculated Spearman’s rank correlations between plasma
concentrations of PG1 and PG2 and tested for differences in the
distribution of concentrations using Wilcoxon tests.
In accord with the matched design of the case–control study, we
used conditional logistic regression models to estimate adjusted
odds ratios (ORs) and 95% confidence intervals (95% CIs) for the
association between gastric cancer risk and plasma concentrations
of PG1, PG2, or the PG1:2 ratio. There are no universally accepted
cutoff points for dichotomising PG1 or the PG1:2 ratio (Weck and
Brenner, 2006), and hence to be consistent with previous studies in
China in which we used Biohit kits (Kamangar et al, 2008;
Ren et al, 2009), we used a cutoff point of o50 for PG1 and o4 for
PG1:2 ratio to define atrophy. There is no established cut point for
PG2, and hence we used the 25th percentile (6.6ngml
–1)a sa n
arbitrary cut point. Furthermore, we analysed plasma PG1, PG2,
and the PG1:2 ratio as quartiles and as continuous variables. For
continuous analyses, consistent with our previous analyses
(Kamangar et al, 2008; Ren et al, 2009), one unit change was
defined as half the distance between the 25th and 75th percentiles.
For PG1, PG2, and the PG1:2 ratio, the scaling of the continuous
variables was 25, 5, and 2.5, respectively. Models were adjusted for
an a priori group of selected variables, including additional
adjustment for age beyond matching (years), plasma H. pylori
positivity, categories of education (elementary school or less,
middle school, high school, and college or higher), frequency of
fruit intake (per week), frequency of vegetable intake (per week),
history of ever smoking (yes vs no), and categories of family
income (o¥10000, ¥10000–20000, ¥20000–30000, and
4¥30000), and PG1 and PG2 were mutually adjusted.
For nonlinear continuous models we used PROG GAM with a
loess smoother in SAS. Degrees of freedom were set to 3 for each
model. The pepsinogen ELISA assays may not provide reliable data
because of nonlinearity at high concentrations. For this reason and
because the analysis is susceptible to outliers, we excluded all
subjects with concentrations of PG1 4200 or PG2 450 for this
analysis (N¼4). After fitting the model, the predicted effect size
and 95% CIs were plotted on the logit scale, the scale on which a
linear association would be detected. The OR comparing any two
points can be calculated by subtracting the logits and exponentiating.
RESULTS
In all, we included 141 gastric adenocarcinoma cases and 282
controls in this analysis. Most (490%) tumours were located in
the noncardia stomach, which precluded stratifying on tumour
location in any analyses. Cases and controls were matched for age,
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The frequency of intake of fresh vegetables and fresh fruits,
and the percentage of ever smokers, the highest educational
attainment, and family income were all similar in the control and
case groups.
The medians (interquartile range) of PG1, PG2, and the PG1:2
ratio among controls were 92.5ngml
–1 (68.1–120.3), 11.4ngml
–1
(6.6–16.9), and 8.7 (6.4–11.4), respectively. Of the 282 controls,
260 (92%) were positive for H. pylori. Of these, 251 tested
positive for CagA strains whereas 9 tested negative. Because only
a small number of subjects tested negative for CagA, we used any
H. pylori positivity for further analyses. Plasma PG1 and PG2
were strongly positively correlated, with a Spearman’s correlation
coefficient of 0.69. In the 22 H. pylori-negative control subjects,
the medians (interquartile range) of PG1, PG2, and the PG1:2
ratio were 77.6ngml
–1 (57.7–92.4), 5.8ngml
–1 (4.9–7.0), and
12.5 (10.3–16.0), respectively. In 260 H. pylori-positive control
subjects, the medians (interquartile range) of PG1, PG2, and
the PG1:2 ratio were 95.4ngml
–1 (70.3–122.7), 11.9ngml
–1
(7.7–17.5), and 8.4 (6.2–10.9), respectively. The differences
between H. pylori-negative and H. pylori-positive subjects were
significant by Wilcoxon test for each of the three measures
(Po0.01).
In all, 92% of controls and 96.5% of cases tested positive for
H. pylori (Table 2). Carriage of H. pylori more than doubled
the gastric cancer risk (crude OR 2.26; 95% CI: 0.84–6.05), but
this association did not reach statistical significance. Further
adjustment for potential confounders including pepsinogen
concentrations did not materially alter the associations.
Table 1 The distribution of potential confounders among gastric cancer
cases and controls nested in the Shanghai Women’s Health Study
Cases Controls P-values*
N 141 282 —
Age, years, mean (s.d.) 58.3 (8.6) 58.3 (8.5) —
Fresh vegetable, servings/week, mean (s.d.) 13.8 (2.5) 13.8 (2.4) 0.46
Fresh fruits, servings/week, mean (s.d.) 5.1 (3.5) 5.3 (3.2) 0.97
Ever smokers, N (%) 9 (6.4) 13 (4.6) 0.49
Education, N (%) 0.28
Elementary school or less 68 (48.2) 113 (40.1)
Middle school 39 (27.7) 83 (29.1)
High school 26 (18.4) 59 (20.9)
College or higher 8 (5.7) 28 (9.9)
Family income, ¥, N (%) 0.84
o10000 29 (20.6) 50 (17.7)
10000 to o20000 55 (39.0) 111 (39.4)
20000 to o30000 41 (29.1) 82 (29.1)
430000 16 (11.4) 39 (13.8)
*P-values come from t-tests for continuous variables and w
2 tests for categorical
variables. Age was matched and not tested for difference.
Table 2 The associations between gastric cancer risk and Helicobacter pylori seropositivity or plasma concentrations of pepsinogen 1 (PG1), pepsinogen 2
(PG2), or PG1:2 ratio in the Shanghai Women’s Health Study
OR (95% CI)
a
Cases Controls Crude Adjusted
H. pylori, N (%)
Negative 5 (3.6) 22 (7.8) Ref Ref
Positive 136 (96.5) 260 (92.2) 2.26 (0.84–6.05) 2.19 (0.80–5.96)
CagA, N(%)
Negative 6 (4.3) 31 (11.0) Ref Ref
Positive 135 (95.7) 251 (89.0) 2.77 (1.13–6.81) 2.72 (1.09–6.78)
PG1 (ngml
–1)
Median (interquartile range (IQR)) 93.0 (69.0–114.0) 92.5 (68.1–120.3) 1.22 (1.02–1.45)
b 1.22 (1.02–1.26)
b
X50, N (%) 120 (85.1) 263 (93.3) Ref Ref
o50, N (%) 21 (14.9) 19 (6.7) 2.65 (1.31–5.38) 4.23 (1.86–9.63)
Quartile 4 (X121) 29 (20.6) 70 (24.8) Ref Ref
Quartile 3 (93–120) 42 (29.8) 71 (25.2) 1.42 (0.82–2.48) 2.00 (1.01–3.97)
Quartile 2 (69–92) 35 (24.8) 70 (24.8) 1.19 (0.66–2.13) 1.71 (0.83–3.55)
Quartile 1 (o68) 35 (24.8) 71 (25.2) 1.20 (0.67–2.15) 1.88 (0.86–4.09)
PG2 (ngml
–1)
Median (IQR) 12.4 (8.7–16.1) 11.4 (6.6–16.9) 1.21 (1.01–1.46)
b 1.20 (1.00–1.44)
b
o6.6, N (%) 73 (25.9) 14 (9.9) Ref Ref
X6.6, N (%) 209 (74.1) 127 (90.1) 3.04 (1.65–5.63) 3.62 (1.85–7.09)
Quartile 1 (o6.6) 13 (9.22) 70 (24.8) Ref Ref
Quartile 2 (6.6–11.3) 51 (36.2) 71 (25.2) 3.65 (1.84–7.24) 3.76 (1.87–7.59)
Quartile 3 (11.4–16.8) 46 (32.6) 70 (24.8) 3.42 (1.67–7.00) 3.98 (1.84–8.61)
Quartile 4 (X16.9) 31 (22.0) 71 (25.2) 2.35 (1.12–4.92) 3.54 (1.44–8.70)
PG1:2 ratio
Median (IQR) 7.2 (5.6–9.2) 8.7 (6.4–11.4) 1.37 (1.18–1.59)
b 1.34 (1.15–1.57)
b
X4, N (%) 126 (89.4) 264 (94) Ref Ref
o4, N (%) 15 (10.6) 18 (6.4) 1.67 (0.84–3.31) 1.60 (0.79–3.22)
Quartile 4 (X11.4) 13 (9.2) 71 (25.2) Ref Ref
Quartile 3 (8.7–11.4) 29 (20.6) 70 (24.8) 2.18 (1.05–4.52) 2.08 (1.00–4.34)
Quartile 2 (6.4–8.7) 40 (28.4) 71 (25.2) 3.14 (1.52–6.48) 2.89 (1.37–6.08)
Quartile 1 (o6.4) 59 (41.8) 70 (24.8) 4.87 (2.41–9.84) 4.54 (2.22–9.32)
aOdds ratios (ORs) and 95% confidence intervals (CIs) come from conditional logistic regression models without or with further adjustment for continuous age, continuous fruit and
vegetable intake, ever smoking, category of education, category of family income, and H. pylori seropositivity, and PG1 and PG2 were mutually adjusted.
bContinuous estimates are
scaled to the average size of the two central quartiles. Specifically, the scales were for changes in concentration of  25 for PG1, 5 for PG2, and  2.5 for the PG1:2 ratio.
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controls) did show a significant association (OR 2.72; 95%
CI: 1.09–6.78).
Median PG1 was similar in cases and controls, but when
modelled as a continuous variable we saw significantly higher risk
of gastric cancer in subjects with lower PG1 concentrations
(Table 2). Using a typical cutoff of o50ngml
–1 we found an
adjusted OR of 4.23 (95% CI: 1.86–9.63) and this value was higher
than the crude estimate. Using quartiles, we saw little evidence of a
trend across the distribution. In a nonlinear continuous model
(Figure 1), it appears that 50ngml
–1 reflects the approximate
inflection point below which the risk of gastric cancer increases.
Median PG2 was similar in cases and controls and we saw
borderline significantly higher risk of gastric cancer in subjects
with higher concentrations of PG2 (Table 2). We estimated the risk
associated with PG2 using the 25th percentile as a cutoff, and PG2
above 6.6ngml
–1 was associated with an elevated risk of 3.62
(1.85–7.09) in adjusted models. Using quartiles, subjects in the
upper three quartiles were at significantly higher risk than those in
the first quartile. For example, subjects in the fourth quartile had
an adjusted OR of 3.54 (95% CI: 1.44–8.70), but there was not a
trend across quartiles; rather there appeared to be a threshold
effect. In the nonlinear continuous model (Figure 1), the inflection
point was B10ngml
–1and subjects below this level seem to have
lower risk of gastric cancer.
When PG1:2 ratio was treated as a dichotomous variable,
having a low PG1:2 ratio (p4 vs higher) was associated with a
nonsignificantly higher risk of gastric cancer, with an adjusted OR
of 1.60 (95% CI: 0.79–3.22; Table 2). When PG1:2 ratio was
treated as quartiles, there was a significant inverse dose-response
association between PG1:2 ratio and gastric cancer risk, with an
adjusted OR of 4.54 (95% CI: 2.22–9.32) comparing the lowest vs
highest quartiles. Likewise, there was a dose-response relationship
between a continuous PG1:2 ratio and risk, with an adjusted OR of
1.34 (95% CI: 1.15–1.57) for each 2.50-unit decrease in PG1:2
ratio. The nonlinear continuous model (Figure 1) suggests a
consistently decreasing risk across the PG1:2 ratio distribution.
To further explore the effects of having either PG1 o50ngml
–1,
PG2 46.6ngml
–1, or both, we fit a joint effects model (Table 3).
Using those with the most favourable profile (PG1 450ngml
–1
and PG2 o6.6ngml
–1) as the referent group, we found that either
PG1 o50ngml
–1 or PG2 46.6ngml
–1 was associated with a
significantly elevated risk of approximately four-fold. When both
adverse conditions were met, the adjusted odds ratio was 15.23
(95% CI: 4.49–51.63). Comparing only the highest risk group to all
others produces an OR of 5.17 (95% CI: 2.01–13.31). The estimates
should be interpreted cautiously because they may be overfit based
on our previous knowledge of the association pattern in these four
groups.
Table 4 presents gastric cancer risk in relation to PG1, PG2, and
the PG1:2 ratio using single cut points during the cumulative 1–5
years of initial follow-up. Although case numbers were small in the
first year of follow-up, and thus the precision of the estimates is
low, it appears that the magnitude of the association with PG1 was
strongest during the first year of follow-up with the OR of 5.18
(95% CI: 0.49–54.76). No clear pattern over time was evident for
PG2. For PG1:2 ratio, the magnitude of the risk estimate was
greatest in the first year of follow-up with the OR of 3.12 (95% CI:
0.47–20.79) and gradually reduces to the overall level with 5 years
of follow-up.
DISCUSSION
Gastric cancer is the second most common cause of cancer death
in the world (Parkin et al, 2005; Kamangar et al, 2006b). Finding
methods for early detection of gastric cancer are particularly
important because of its high incidence and low survival rates
(Cunningham et al, 2005). In some countries with very high risk of
gastric cancer, such as Japan, early detection programmes use
upper gastrointestinal endoscopies to search for early cancerous
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Figure 1 Nonlinear continuous associations between concentrations of
PG1, PG2, and the PG1:2 ratio and odds of gastric cancer in the Shanghai
Women’s Health Study. The association point estimate and 95%
confidence intervals between plasma concentrations and odds of gastric
cancer are plotted on the logit scale as black and grey circles, respectively.
Vertical dotted lines indicate the quartile boundaries for each analyte. The
odds ratio for the change between any two points can be calculated by
subtracting the logits and exponentiating.
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endoscopies in the entire population is not always feasible (Leung
et al, 2008). Therefore, use of biological markers such as
circulating pepsinogens, which indicate atrophic gastritis and the
presence of other early lesions, have been used as a method to
triage people who need endoscopies (Leung et al, 2008).
In severe atrophic gastritis, the antral-type mucosa (Kimura,
1972), which secretes only PG2, replaces fundic mucosa, which
secretes both PG1 and PG2. H. pylori-induced inflammation of the
foveolar compartment may also result in higher PG2. As a result, in
subjects with severe atrophic gastritis, circulating PG1 levels are
reduced substantially but circulating PG2 levels remain relatively
constant (Samloff et al, 1982). Therefore, both PG1 and the PG1:2
ratio decrease (Samloff et al, 1982; Ley et al, 2001) and are
associated with an elevated risk of gastric cancer (Stemmermann
et al, 1987; Parsonnet et al, 1993; You et al, 1993; Fukuda et al,
1995; Ye et al, 2004; Kokkola et al, 2005; Nomura et al, 2005;
Shiotani et al, 2005; Watabe et al, 2005; Oishi et al, 2006). Several
studies have suggested that PG1:2 ratio is a more accurate marker
for both atrophic gastritis (Samloff et al, 1982) and future risk of
cancer (Stemmermann et al, 1987; You et al, 1993; Fukuda et al,
1995) than PG1 alone. Our results show that H. pylori positivity is
associated with increased concentrations of both PG1 and PG2.
The increase, however, is greater for PG2 than PG1 so that
H. pylori is associated with a decreased PG1:2 ratio. A consistent
pattern appears to be emerging, as two other recent large studies
(Weck et al, 2007; Ren et al, 2009) also reported an association of
H. pylori with increased circulating PG1 and PG2 but decreased
PG1:2 ratio.
We examined PG1 and PG2 independently and jointly for their
associations with gastric cancer risk. We found evidence of
threshold effects for each of the pepsinogen concentrations such
that an elevated risk was associated with PG1 o50ngml
–1or PG2
X6.6ngml
–1. These two phenomena appear to be independent
because using each in a single risk model produced significant
associations with gastric cancer risk (adjusted estimates in Table 2).
When PG1 and PG2 were examined as a ratio, there is a nearly
linear association between PG1:2 ratio and gastric cancer risk. Our
results show that using either PG1:2 ratio quartiles Q1 vs Q4 (OR
4.54; 95% CI: 2.22–9.32) or the two cut points of PG1 o50 and
PG2 46.6 (OR 5.17; 95% CI: 2.01–13.31) is more strongly
associated with gastric cancer risk than PG1:2 ratio o4 (OR
1.60; 95% CI: 0.79–3.22).
In unadjusted analyses, H. pylori increased gastric cancer risk by
over two-fold but this association was not statistically significant.
H. pylori is an established cause of gastric cancer, but some studies
from China have shown a lower relative risk of gastric cancer
associated with this bacterium compared with results reported
from Western countries (Yuan et al, 1999; Kamangar et al,
2006a). The direction and magnitude of the association we
observed is consistent with previous studies from China (Yuan
et al, 1999). The lack of significance is perhaps because few people
were negative for H. pylori and consequently there was low power to
detect an association. When we used CagA positivity alone to define
this exposure, a lower percentage of controls tested positive and the
association became significant. This phenomenon is similar to other
highly infected, high gastric cancer risk populations.
This study has several strengths that include its prospective
design, collection of data on potential confounders, and rigorous
methods for ascertaining outcomes. There are also some limita-
tions. Most importantly, the sample size was modest that limited
our ability to analyse data by subsites of gastric cancer and
subtypes of H. pylori. Nevertheless, our numbers are larger than
many of the recently published prospective studies of gastric
cancer. Furthermore, here we only studied women and these
results may not be directly applicable to men, but as noted above
our results are similar to previous publications that studied both
men and women.
In summary, the results of this study confirm previous findings
that lower serum or plasma PG1:2 ratios indicate higher risk of
Table 3 The associations between gastric cancer risk and plasma concentrations of pepsinogen 1 (PG1) and pepsinogen 2 (PG2) in the Shanghai
Women’s Health Study using single cut points
Cases Controls
OR (95% CI)
a
N (%) N (%) Crude Adjusted
PG1 450 and PG2 o6.6ngml
–1 8 (6) 61 (22) Ref Ref
PG1 o50 and PG2 o6.6ngml
–1 6 (4) 12 (4) 4.56 (1.25–16.58) 4.38 (1.17–16.36)
PG1 450 and PG2 46.6ngml
–1 112 (79) 202 (72) 4.01 (1.86–8.66) 3.67 (1.68–8.01)
PG1 o50 and PG2 46.6ngml
–1 15 (11) 7 (2) 16.30 (4.90–54.24) 15.23 (4.49–51.63)
aOdds ratios (ORs) and 95% confidence intervals (CIs) come from conditional logistic regression models without or with further adjustment for continuous age, continuous fruit
and vegetable intake, ever smoking, category of education, category of family income, Helicobacter pylori seropositivity, and where appropriate pepsinogens 1 and 2 concentration.
Table 4 The associations between pepsinogen 1 (PG1), pepsinogen 2 (PG2), and the PG1:2 ratio and gastric cancer risk in the Shanghai Women’s
Health Study by follow-up time
OR (95% CI)
a
Years of follow-up Cases PG1 o50 PG2 46.6 PG1:2 ratio o4
p1 16 5.18 (0.49–54.76) 2.40 (0.44–13.08) 3.12 (0.47–20.79)
p2 28 4.50 (0.81–25.05) 3.84 (0.90–16.35) 2.92 (0.59–14.38)
p3 48 2.74 (0.82–9.19) 1.73 (0.68–4.39) 2.44 (0.70–8.47)
p4 75 3.29 (1.17–9.27) 2.69 (1.24–5.83) 2.96 (1.05–8.35)
p5 90 3.95 (1.49–10.48) 3.07 (1.42–6.65) 1.76 (0.73–4.26)
Overall 141 4.23 (1.86–9.63) 3.62 (1.85–7.09) 1.60 (0.79–3.22)
aOdds ratios (ORs) and 95% confidence intervals (CIs) come from conditional logistic regression models with further adjustment for continuous age, continuous fruit and
vegetable intake, ever smoking, category of education, category of family income, Helicobacter pylori seropositivity, and where appropriate pepsinogens 1 and 2 concentration.
Plasma pepsinogens and gastric cancer risk
CC Abnet et al
1515
British Journal of Cancer (2011) 104(9), 1511–1516 & 2011 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
ygastric cancer and suggest that using this marker as a continuous
variable is more informative of cancer risk than using it as a
dichotomous variable. To our knowledge, our results show for the
first time that using PG1 and PG2 as separate markers may show
stronger associations with gastric cancer, but this finding needs to
be replicated in other studies.
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